SavedAdd your journal

Journals / İstanbul Medical Journal / 2019 / Cilt: 20 - Sayı: 2

Evaluation of Receptor Activator of Nuclear Factor Kappa-B Ligand and Osteoprotegerin Levels in Patients with Type 2 Diabetes Mellitus Treated with Oral Anti-diabetics (Sulfonylurea and Metformin) or Insulin: Bone Tissue Perspective

Oral Anti-diyabetik (Sülfonilüre, Metformin) ya da İnsülin ile Tedavi Edilen Tip 2 Diabetes Mellituslu Hastalarda Reseptör Aktivatör Nükleer Kappa-B Ligandı, Osteoprotegerin Düzeylerinin Kemik Dokusu Yönünden İncelenmesi

Macit KOLDAŞ
Mustafa VELET
Muhammed Emin DÜZ
Cihan COŞKUN
Alper GÜMÜŞ
Pages
130–135
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: We believe that RANKL and OPG levels are higher in patients with poor glycemic control and that they may be indicators of disease severity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: We aimed to investigate the levels of receptor activator of nuclear factor kappa-b ligand (RANKL) and osteoprotegerin (OPG) in order to evaluate the negativeeffects of type 2 diabetes mellitus on bone health and their relationship to the severity of disease based on the treatment.
📊
Key Findings & Data:We also evaluated the relationship between hemoglobin A1c (HbA1c), parathyroid hormone (PTH) and bone specific alkaline phosphatase (BAP) levels and RANKL and OPG levels.
💡
Conclusion & Impact:Conclusion: We believe that RANKL and OPG levels are higher in patients with poor glycemic control and that they may be indicators of disease severity.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: We aimed to investigate the levels of receptor activator of nuclear factor kappa-b ligand (RANKL) and osteoprotegerin (OPG) in order to evaluate the negativeeffects of type 2 diabetes mellitus on bone health and their relationship to the severity of disease based on the treatment. We also evaluated the relationship between hemoglobin A1c (HbA1c), parathyroid hormone (PTH) and bone specific alkaline phosphatase (BAP) levels and RANKL and OPG levels. Methods: The study group consisted of 19 volunteers (15 females and 4 males) and 65 patients with type 2 diabetes mellitus (49 females and 16 males). In order to evaluate the relationship between the treatment and the disease severity, the patient group was divided into two subgroups: patients treated with oral anti-diabetics (OAD) (sulfonylurea and metformin) or insulin. The levels of glucose, calcium, phosphorus, HbA1c, BAP, PTH, RANKL and OPG were compared. Results: The RANKL and OPG levels of patients treated with insulin were significantly higher than the control group (p=0.008, p=0.033, respectively). However, there was no significant difference in the OAD group for both parameters (p=0.1, p=0.46, respectively). There was no significantdifference between the groups in terms of PTH and BAP levels (p=0.97, p=0.66, respectively). Conclusion: We believe that RANKL and OPG levels are higher in patients with poor glycemic control and that they may be indicators of disease severity.

Özet

Amaç: Tip 2 diabetes mellitusun kemik sağlığı üzerindeki olumsuz etkilerini, tedaviye bağlı olarak hastalığın ağırlığı ile olan ilişkisini değerlendirmek için reseptör aktivatör nükleer kappa-B ligandı (RANKL) ile birlikte osteoprotegerin (OPG) düzeylerini araştırdık. Ayrıca hemoglobin A1c (HbA1c), paratiroid hormon (PTH), kemik spesifik alkalen fosfataz (BAP) düzeylerinin hem RANKL hem de OPG düzeyleri ile ilişkisini değerlendirmektir. Yöntemler: Çalışma grubunu 19 gönüllüden (15 kadın, 4 erkek), hasta grubunu ise 65 tip 2 diabetes mellituslu (49 kadın, 16 erkek) hasta oluşturdu. Uygulanan tedavi ile hastalık ağırlığı arasındaki ilişkiyi değerlendirebilmek için hasta grubu oral anti diyabetik alan (sülfonilüre, metformin) ya da insülin kullananlar olmak üzere iki alt gruba ayrılarak glikoz, kalsiyum, fosfor, HbA1c, BAP, PTH, RANKL, OPG düzeyleri karşılaştırıldı. Bulgular: Kan glikozun insülinle düzenlenen tip 2 diabetes mellituslu hastaların hem RANKL hem de OPG düzeyleri kontrol grubuna göre anlamlı derecede yüksekti (sırasıyla; p=0,008, p=0,033). Ancak OAD grubu her iki parametre için de farklı değildi (sırasıyla; p=0,1, p=0,46). Gruplar arasında PTH ve BAP değerleri açısından anlamlı fark yoktu (sırasıyla; p=0,97, p=0,66). Sonuç: RANKL ile OPG düzeylerinin, glisemik kontrol bozukluğu olan hastalarda daha yüksek olduğunu, hastalık şiddetinin birer göstergesi olabileceğini düşünüyoruz.

🔖

Cite This Article

KOLDAŞ, M., VELET, M., DÜZ, M. E., COŞKUN, C., GÜMÜŞ, A. (2022). Evaluation of Receptor Activator of Nuclear Factor Kappa-B Ligand and Osteoprotegerin Levels in Patients with Type 2 Diabetes Mellitus Treated with Oral Anti-diabetics (Sulfonylurea and Metformin) or Insulin: Bone Tissue Perspective. İstanbul Medical Journal, Cilt: 20 - Sayı: 2, 130–135. https://ajindex.com/articles/551977

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Global report on diabetes. World Health Organization, Geneva, 2016 http:// apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf. Received 12.03.2016
  2. Onat A, Karakoyun S, Akbaş T, Karadeniz FÖ, Karadeniz Y, Çakır H, et al. Turkish adult risk factor survey 2014: Overall mortality and coronary disease incidence in Turkey’s geographic regions. Turk Kardiyol Dern Ars 2015; 43: 326-32
  3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009; 32(Suppl 1): 62-7
  4. Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res Clin Pract 2005; 67: 3-21
  5. Ginaldi L, Martinis DM. Osteoimmunology and beyond. Curr Med Chem 2016; 23: 3754-74
  6. Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther 2008; 88: 1322-35
  7. Motyla KJ, Laura R, Mccabe AB, Schwartzc AV. Bone and glucose metabolism: A two-way street. Arch Biochem Biophys 2010; 503: 2-10
  8. Schwetz V, Pıeber T, Obermayer-Pıetsch B. The endocrine role of the skeleton: Background and clinical evidence. Eur J Endocrinol 2012; 166: 959-67
  9. Hough, SF. Diabetic osteopenia. Diabetes Res Clin Pract 1989; 7: 161-2
  10. Qiu S, Rao DS, Palnitkar S, Parfitt AM. Differences in osteocyte and lacunar density between black and white American women. Bone 2006; 38: 130-5
  11. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-76
  12. Bell NH. RANK ligand and the regulation of skeletal remodeling. J Clin Invest 2003; 111: 1120-2 13. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-19
  13. Tirosh A. High RANKs for diabetes and osteoporosis. science translational medicine. 2013; 177; 177-49
  14. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes and Development 1998; 12: 1260-8
  15. Galluzzi F, Stagi S, Salti R, Toni S, Piscitelli E, Simonini G, et al. Osteoprotegerin serum levels in children with type 1 diabetes: A potential modulating role in bone status. Eur J Endocrinol 2005; 153: 879-85
  16. García-Hernández A, Arzate H, Gil-Chavarría I, Rojo R, Moreno-Fierros L. High glucose concentrations alte